XBiotech, Maker of HS Drug Candidate Stock Up

Mar 31, 2019 | Hidradenitis Suppurativa, Leading Pharma, Pharma Watch, XBiotech

XBitoech stock was up 2.23% or $0.24 during the last trading session, reaching $11.02. About 120,805 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since March 29, 2018 and is uptrending. It has outperformed by 86.16% the S&P500.

Some Historical XBIT News

02/04/2018 – XBiotech Inc has obtained an exclusive, worldwide license from CT Atlantic AG

16/04/2018 – XBiotech Inc announces upcoming Phase 2 clinical studies in patients with moderate to sever Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS)

02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer

16/04/2018 – XBiotech Inc CO would evaluate a new subcutaneous formulation of CO’s true human monoclonal antibody, MABP1, in two sperate Phase 2 studies

02/04/2018 – XBiotech will use its technology ot advance development of true human (TM) ANTI-NY-ESO-1 Monoclonal Antibody, 12D7

02/04/2018 – XBiotech Inc has obtained an exclusive, worldwide license from CT Atlantic AG, a swiss biotechnology company

22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis

16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

02/04/2018 – XBiotech Inc licenses ANTI-NY-ESO-1 antibody from CT ATLANTIC. The move comes after 7 months positive chart setup for the $397.25 million company. It was reported on Mar, 29 by Barchart.com. We have $11.46 PT which if reached, will make NASDAQ:XBIT worth $15.89M more.

0 Comments

Pin It on Pinterest